Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 1.00 |
| ▸ | CHAT | P28329 | 4/20 | 0.85 |
| ▸ | USP2 | O75604 | 2/20 | 0.85 |
| ▸ | APEX1 | P27695 | 2/20 | 0.85 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.82 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.82 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.77 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.77 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.77 |
| ▸ | FUT8 | Q9BYC5 | 2/20 | 0.77 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.71 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cibacron Blue SCHEMBL30286286 | 1.00 | HPGDS (1.00) | HPGDSCHATUSP2APEX1ENPP3 | |
| Cibacron Blue SCHEMBL4350042 | 1.00 | HPGDS (1.00) | HPGDSCHATUSP2APEX1ENPP3 | |
| Cibacron Blue SCHEMBL29373073 | 1.00 | HPGDS (1.00) | HPGDSCHATUSP2APEX1ENPP3 | |
| SCHEMBL17000442 | 0.97 | HPGDS (0.95) | HPGDSCHATUSP2APEX1ENPP3 | |
| SCHEMBL13213990 | 0.95 | HPGDS (0.91) | HPGDSCHATUSP2APEX1ENPP3 | |
| SCHEMBL13046386 | 0.94 | CHAT (0.90) | HPGDSCHATUSP2APEX1ENPP3 | |
| SCHEMBL12662265 | 0.93 | HPGDS (0.86) | HPGDSCHATUSP2APEX1ENPP3 | |
| SCHEMBL11885371 | 0.93 | HPGDS (0.86) | HPGDSCHATUSP2APEX1ENPP3 | |
| SCHEMBL19524846 | 0.93 | HPGDS (0.86) | HPGDSCHATUSP2APEX1ENPP3 | |
| SCHEMBL13856914 | 0.92 | CHAT (1.00) | HPGDSCHATUSP2APEX1ENPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618855-B2 | Serum protein biomarker panel for idiopathic pulmonary fibrosis | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4713349-A1 | METHOD FOR ISOLATING FETUIN-A | PreviPharma GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4683579-A1 | RELIEVE BACK PAIN AND/OR REBUILDING INTERVERTERAL DISC | Yeung, Jeffrey E. (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025245356-A1 | NITRIC OXIDE RELEASING ARTICLES WITH ENHANCED ALBUMIN AFFINITY AND METHODS FOR MAKING AND USING THE SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250332292-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4639175-A1 | METHOD TO DETECT AND TREAT PERIPHERAL NEUROPATHY | Ohio State Innovation Foundation (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12422433-B2 | Blood biomarker that predicts persistent cognitive dysfunction after concussion | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024235911-A1 | METHOD FOR ISOLATING FETUIN-A | PREVIPHARMA CONSULTING GMBH (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4427045-A1 | METHOD FOR THE DIAGNOSIS OF MELANOMA | IMG Pharma Biotech, S.L. (ES) | 2024-09-11 | — | — | EP | disclosed |
| US-12085565-B2 | SNTF is a blood biomarker for the diagnosis and prognosis of sports-related concussion | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-09-10 | — | — | US | disclosed |
| US-11899027-B2 | Diagnostic methods based on lipid profiles | RUBIO METABOLOMICS, S.L.U. (ES) | 2024-02-13 | — | — | US | disclosed |
| US-20230393133-A1 | BLOOD BIOMARKER THAT PREDICTS PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-12-07 | — | — | US | disclosed |
| US-11779643-B2 | Methods and compositions for the treatment of an inflammatory bowel disease | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-10-10 | — | — | US | disclosed |
| US-11761959-B2 | Blood biomarker that predicts persistent cognitive dysfunction after concussion | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-09-19 | — | — | US | disclosed |
| US-11725026-B2 | Compositions and methods for inhibiting lactate dehydrogenase a activity | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2023078892-A1 | METHOD FOR THE DIAGNOSIS OF MELANOMA | IMG PHARMA BIOTECH, S.L. (ES) | 2023-05-11 | — | — | WO | disclosed |
| EP-3418430-B1 | BLOOD BIOMARKERS THAT PREDICT PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSION | UNIV PENNSYLVANIA (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220113321-A1 | NEURAL PROTEINS AS BIOMARKERS FOR NERVOUS SYSTEM INJURY AND OTHER NEURAL DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| CN-110003172-B | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | 同步制药公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332292-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | CD44, CRYAA, ILK | HPGDS 120/4885CHAT 1055/4885USP2 381/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | HPGDS 1858/4885CHAT 485/4885USP2 1349/4885 |
| US-12618855-B2 | Serum protein biomarker panel for idiopathic pulmonary fibrosis | SERPINA6, PITPNB, MYO3A | HPGDS 3842/4885CHAT 3410/4885USP2 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.